Main Article Content


Prion diseases or transmissible spongiform encephalopathies (TSEs) are a family of rare progressive neurodegenerative disorders that affect both humans and animals. They are distinguished by long incubation periods, characteristic spongiform changes associated with neuronal loss, and a failure to induce inflammatory response. Prion diseases in animals, Scrapie in sheep, chronic wasting disease (CWD) in deer, bovine spongiform encephalopathy (commonly known as "mad cow disease") in cattle, and Creutzfeldt-Jakob disease in humans are all examples of infectious diseases. The prion protein (PrP) was identified in a patient in 2015, and it was previously believed to be the cause of all known mammalian prion diseases. However, The protein alpha-synuclein, which is thought to be responsible for MSA, was suggested to be the cause of the disease in 2015.


Prions 1 PrPC Function 2 PrPC Structure 3 Scrapie 4

Article Details

How to Cite
Yasir, S. J., & Al- Makhzoomy, T. A. K. (2021). Prions: Some Details and Diseases. Medical Science Journal for Advance Research, 2(3), 80–94.


  1. "Prion diseases". Diseases and conditions. National Institute of Health.
  2. "Prion diseases". United States Centers for Disease Control and Prevention. 2019-05-03.
  3. "What Is a Prion?". Scientific American. Retrieved 15 May 2018.
  4. "Prion infectious agent". Encyclopaedia Britannica. Retrieved 15 May 2018.
  5. Prusiner SB (June 1991). "Molecular biology of prion diseases". Science. 252 (5012): 1515–22.
  6. Prusiner SB (November 1998). "Prions". Proceedings of the National Academy of Sciences of the United States of America. 95 (23): 13363–83.
  7. Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN, Geschwind DH, Glidden DV, Halliday GM, Middleton LT, Gentleman SM, Grinberg LT, Giles K (September 2015). "Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism". Proceedings of the National Academy of Sciences of the United States of America. 112 (38): E5308
  8. "How Prions Came to Be: A Brief History – Infectious Disease: Superbugs, Science, & Society". Retrieved 2021-09-17.
  9. Alper T, Cramp WA, Haig DA, Clarke MC (May 1967). "Does the agent of scrapie replicate without nucleic acid?". Nature. 214 (5090): 764–66.
  10. Griffith JS (September 1967). "Self-replication and scrapie". Nature. 215 (5105): 1043–44.
  11. Field EJ (September 1966). "Transmission experiments with multiple sclerosis: an interim report". British Medical Journal. 2 (5513): 564–65.
  12. Adams DH, Field EJ (September 1968). "The infective process in scrapie". Lancet. 2 (7570): 714–16.
  13. Field EJ, Farmer F, Caspary EA, Joyce G (April 1969). "Susceptibility of scrapie agent to ionizing radiation". Nature. 5188. 222 (5188): 90–91. Bibcode:1969Natur.222...90F. doi:10.1038/222090a0. PMID 4975649. S2CID 4195610.
  14. Griffith JS (Sep 1967). "Self-replication and scrapie". Nature. 215 (5105): 1043–44.
  15. Bolton D (January 1, 2004). "Prions, the Protein Hypothesis, and Scientific Revolutions". In Nunnally BK, Krull IS (eds.). Prions and Mad Cow Disease. Marcel Dekker. pp. 21–60. ISBN 978-0-203-91297-3 – via ResearchGate.
  16. Crick F (August 1970). "Central dogma of molecular biology". Nature. 227 (5258): 561–63.
  17. Coffin JM, Fan H (September 2016). "The Discovery of Reverse Transcriptase". Annual Review of Virology. 3 (1): 29–51.
  18. Taubes G (December 1986). "The game of name is fame. But is it science?". Discover. 7 (12): 28–41.
  19. Atkinson CJ, Zhang K, Munn AL, Wiegmans A, Wei MQ (2016). "Prion protein scrapie and the normal cellular prion protein". Prion. 10 (1): 63–82.
  20. "The Nobel Prize in Physiology or Medicine, 1997". Retrieved 2010-02-28. The Nobel Prize in Physiology or Medicine 1997 was awarded to Stanley B. Prusiner 'for his discovery of Prions - a new biological principle of infection.'
  21. S. L. Shyng, M. T. Huber, and D. A. Harris, “A prion protein cycles between the cell surface and an endocytic compartment in cultured neuroblastoma cells,” Journal of Biological Chemistry, vol. 268, no. 21, pp. 15922–15928, 1993.
  22. R. Cappai and S. J. Collins, “Structural biology of prions,” Contributions to Microbiology, vol. 11, pp. 14–32, 2004.
  23. C. J. Sigurdson and A. Aguzzi, “Chronic wasting disease,” Biochimica et Biophysica Acta, vol. 1772, no. 6, pp. 610–618, 2007.
  24. Fred F. Damberger, Barbara Christen, Daniel R. Pérez, Simone Hornemann, and Kurt Wüthrich. Cellular prion protein conformation and function .2011. PNAS 108 (42) 17308-17313;
  25. C. A. Koch, D. Anderson, M. F. Moran, C. Ellis, and T. Pawson, “SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins,” Science, vol. 252, no. 5006, pp. 668–674, 1991.
  26. S. Mouillet-Richard, M. Ermonval, C. Chebassier et al., “Signal transduction through prion protein,” Science, vol. 289, no. 5486, pp. 1925–1928, 2000.
  27. A. Aguzzi, F. Baumann, and J. Bremer, “The prion's elusive reason for being,” Annual Review of Neuroscience, vol. 31, pp. 439–477, 2008.
  28. m.E. Graner, A. F. Mercadante, S. M. Zanata et al., “Cellular prion protein binds laminin and mediates neuritogenesis,” Molecular Brain Research, vol. 76, no. 1, pp. 85–92, 2000.
  29. S. Puig and D. J. Thiele, “Molecular mechanisms of copper uptake and distribution,” Current Opinion in Chemical Biology, vol. 6, no. 2, pp. 171–180, 2002.
  30. M. D. Harrison and C. T. Dameron, “Molecular mechanisms of copper metabolism and the role of the menkes disease protein,” Journal of Biochemical and Molecular Toxicology, vol. 13, no. 2, pp. 93–106, 1999.
  31. D. J. Waggoner, T. B. Bartnikas, and J. D. Gitlin, “The role of copper in neurodegenerative disease,” Neurobiology of Disease, vol. 6, no. 4, pp. 221–230, 1999.
  32. E. D. Walter, M. Chattopadhyay, and G. L. Millhauser, “The affinity of copper binding to the prion protein octarepeat domain: evidence for negative cooperativity,” Biochemistry, vol. 45, no. 43, pp. 13083–13092, 2006.
  33. E. Quaglio, R. Chiesa, and D. A. Harris, “Copper converts the cellular prion protein into a protease-resistant species that is distinct from the scrapie isoform,” Journal of Biological Chemistry, vol. 276, no. 14, pp. 11432–11438, 2001.
  34. P. C. Pauly and D. A. Harris, “Copper stimulates endocytosis of the prion protein,” Journal of Biological Chemistry, vol. 273, no. 50, pp. 33107–33110, 1998.
  35. L. Westergard, H. M. Christensen, and D. A. Harris, “The cellular prion protein PrPc: its physiological function and role in disease,” Biochimica et Biophysica Acta, vol. 1772, no. 6, pp. 629–644, 2007
  36. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (February 2009). "Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers". Nature. 457 (7233): 1128–32.
  37. Olanow CW, Brundin P (2013). "Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?". Movement Disorders. 28 (1): 31–40.
  38. Goedert M (2015). "NEURODEGENERATION.Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ,tau, and α synuclein". Science. 349 (6248): 1255555.
  39. Lee S, Kim HJ (2015). "Prion-like Mechanism in Amyotrophic Lateral Sclerosis: are Protein Aggregates the Key?". Experimental Neurobiology. 24 (1): 1–7.
  40. Alberti S, Halfmann R, King O, Kapila A, Lindquist S (2009). "A systematic survey identifies prions and illuminates sequence features of prionogenic proteins". Cell. 137 (1): 146–58.
  41. Aguzzi A (2008). "Unraveling prion strains with cell biology and organic chemistry". Proceedings of the National Academy of Sciences of the United States of America. 105 (1): 11–12.
  42. Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C (February 2010). "Darwinian evolution of prions in cell culture". Science. 327 (5967): 869–72.
  43. Hsiao K, Baker HF, Crow TJ, et al. Linkage of a prion protein missense variant to Gerstmann-Sträussler syndrome. Nature 1989;338:342-345
  44. Dlouhy SR, Hsiao K, Farlow MR, et al. Linkage of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene. Nat Genet 1992;1:64-67
  45. Petersen RB, Tabaton M, Berg L, et al. Analysis of the prion protein gene in thalamic dementia. Neurology 1992;42:1859-1863
  46. Poulter M, Baker HF, Frith CD, et al. Inherited prion disease with 144 base pair gene insertion. 1. Genealogical and molecular studies. Brain 1992;115:675-685
  47. Gabizon R, Rosenmann H, Meiner Z, et al. Mutation and polymorphism of the prion protein gene in Libyan Jews with Creutzfeldt-Jakob disease (CJD). Am J Hum Genet 1993;53:828-835
  48. Roos R, Gajdusek DC, Gibbs CJ Jr. The clinical characteristics of transmissible Creutzfeldt-Jakob disease. Brain 1973;96:1-20
  49. Masters CL, Gajdusek DC, Gibbs CJ Jr. Creutzfeldt-Jakob disease virus isolations from the Gerstmann-Sträussler syndrome with an analysis of the various forms of amyloid plaque deposition in the virus-induced spongiform encephalopathies. Brain 1981;104:559-588
  50. Hsiao K, Doh-ura K, Kitamoto T, Tateishi J, Prusiner SB. A prion protein amino acid substitution in ataxic Gerstmann-Sträussler syndrome. Ann Neurol 1989;26:137-137 abstract.
  51. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017.
  52. "Creutzfeldt-Jakob Disease, Classic (CJD)". CDC. 2 October 2018. Manix, Marc; Kalakoti, Piyush; Henry, Miriam; Thakur, Jai; Menger, Richard; Guthikonda, Bharat; Nanda, Anil (2015-11-01). "Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy". Neurosurgical Focus. 39 (5): E2.
  53. Brandel J, Vlaciu M, Culeux A, Belondrade M, Grznarova K, Plu I, Levasseur M, Haik S (July 2, 2020). "Variant Creutzfeldt–Jakob Disease Diagnosed 7.5 Years after Occupational Exposure". New England Journal of Medicine. 383 (1): 83–85.
  54. "Transfusion Handbook/ 5.4: Variant Creutzfeldt–Jakob disease (vCJD)". Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. 4 February 2014.
  55. "A 49-Year-Old Man With Forgetfulness and Gait Impairment".17. Archived from the original on 20-07-06.
  56. Murray ED, Buttner N, Price BH. (2012) Depression and Psychosis in Neurological Practice. In: Neurology in Clinical Practice, 6th Edition. Bradley WG, Daroff RB, Fenichel GM, Jankovic J (eds.) Butterworth Heinemann. April 12, 2012.
  57. Brown P, Cathala F, Castaigne P, Gajdusek DC (November 1986). "Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases". Annals of Neurology. 20 (5): 597–602.
  58. Gambetti, Pierluigi. "Creutzfeldt–Jakob Disease (CJD)". The Merck Manuals: Online Medical Library. 2011.Archived from the original on 2011-06-04.
  59. Atalay, Fatma Oz; Tolunay, Sahsine; Ozgun, Gonca; Bekar, Ahmet; Zarifoglu, Mehmet (2013). "Creutzfeldt-jakob disease: report of four cases and review of the literature". Turkish Journal of Pathology. 31 (2): 148–152.
  60. "Fatal familial insomnia". 2019. Genetic and Rare Diseases Information Center (GARD) – an NCATS Program.
  61. "Fatal Insomnia – Neurologic Disorders". 2019.Merck Manuals Professional Edition.
  62. "Fatal Familial Insomnia". 2019. NORD (National Organization for Rare Disorders).
  63. "What is fatal familial insomnia?". Healthline. 26 January 2018.
  64. "Fatal Insomnia". Merck Manual. Retrieved 4 May 2018.
  65. Schenkein J, Montagna P (2006). "Self management of fatal familial insomnia. Part 1: what is FFI?". MedGenMed. 8 (3):65.
  66. Max, D. T. (2007). The Family that Couldn't Sleep: A medical mystery. New York: Random House Trade Paperbacks. p. 4.
  67. "The epidemiology of kuru in the period 1987 to 1995", 2019.Department of Health (Australia).
  68. Hoskin, J.O.; Kiloh, L.G.; Cawte, J.E. (1969). "Epilepsy and guria: The shaking syndromes of New Guinea". Social Science & Medicine. 3 (1): 39–48.
  69. Scott, Graham (1978). The Fore Language of Papua New Guinea. Pacific Linguistics. pp. 2, 6.
  70. Whitfield, Jerome T; Pako, Wandagi H; Collinge, John; Alpers, Michael P (2008). "Mortuary rites of the South Fore and kuru". Philosophical Transactions of the Royal Society B: Biological Sciences. 363 (1510): 3721–3724.
  71. Bichell, Rae Ellen (2016). "When People Ate People, A Strange Disease Emerged". Retrieved 2018-04-08.
  72. "Kuru". MedlinePlus Medical Encyclopedia. Retrieved 2016-11-14.
  73. Alpers, MP (2007). "A history of kuru". Papua and New Guinea Medical Journal. 50 (1–2): 10–9.
  74. Rense, Sarah (2016). "Here's What Happens to Your Body When You Eat Human Meat". Esquire.
  75. A life of determination". Monash University — Faculty of Medicine, Nursing and Health Sciences. 2009-02-23. Archived from the original on 2015-12-10.
  76. Collinge, John; Whitfield, Jerome; McKintosh, Edward; Beck, John; Mead, Simon; Thomas, Dafydd J; Alpers, Michael P (2006). "Kuru in the 21st century—an acquired human prion disease with very long incubation periods". The Lancet. 367 (9528): 2068–2074.
  77. Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, Cohen FE, DeArmond SJ, Prusiner SB (1995). "Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein". Cell. 83 (1): 79–90.
  78. Johnson CJ, Pedersen JA, Chappell RJ, McKenzie D, Aiken JM (2007). "Oral transmissibility of prion disease is enhanced by binding to soil particles". PLOS Pathogens. 3 (7): e93
  79. Tamgüney G, Miller MW, Wolfe LL, Sirochman TM, Glidden DV, Palmer C, Lemus A, DeArmond SJ, Prusiner SB (September 2009). "Asymptomatic deer excrete infectious prions in faeces". Nature. 461 (7263): 529–32.
  80. Haybaeck J, Heikenwalder M, Klevenz B, Schwarz P, Margalith I, Bridel C, Mertz K, Zirdum E, Petsch B, Fuchs TJ, Stitz L, Aguzzi A (2011). "Aerosols transmit prions to immunocompetent and immunodeficient mice". PLOS Pathogens. 7 (1): e1001257.
  81. Van Dorsselaer A, Carapito C, Delalande F, Schaeffer-Reiss C, Thierse D, Diemer H, McNair DS, Krewski D, Cashman NR (2011). "Detection of prion protein in urine-derived injectable fertility products by a targeted proteomic approach". PLOS ONE. 6 (3): e17815.
  82. Westergard L, Christensen HM, Harris DA (2007) The cellular prion protein (PrPC): Its physiological function and role in disease. Biochim Biophys Acta 1772:629–644.
  83. Aguzzi A, Baumann F, Bremer J (2008) The prion’s elusive reason for being. Annu Rev Neurosci 31:439–477.
  84. a↵Linden R, et al. (2008) Physiology of the prion protein. Physiol Rev 88:673–728.
  85. Riek R, et al. (1996) NMR structure of the mouse prion protein domain PrP(121–231) Nature 382:180–182.
  86. Riek R, Hornemann S, Wider G, Glockshuber R, Wüthrich K (1997) NMR characterization of the full-length recombinant murine prion protein, mPrP (23–231) FEBS Lett 413:282–288.
  87. Hornemann S, Schorn C, Wüthrich K (2004) NMR structure of the bovine prion protein isolated from healthy calf brains. EMBO Rep 5:1159–1164.
  88. Schätzl HM, Da Costa M, Taylor L, Cohen FE, Prusiner SB (1995) Prion protein gene variation among primates. J Mol Biol 245:362–374.
  89. James TL, et al. (1997) Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. Proc Natl Acad Sci USA 94:10086–10091.
  90. Zahn R, et al.(2000) NMR solution structure of the human prion protein. Proc Natl Acad Sci USA 97:145–150.
  91. LópezGarcía F, Zahn R, Riek R, Wüthri ch K.(2000) NMR structure of the bovine prion protein. Proc Natl Acad Sci USA 97:8334–8339.
  92. Lysek DA, et al.(2005) Prion protein NMR structures of cats, dogs, pigs, and sheep. Proc Natl Acad Sci USA 102:640–645.
  93. Gossert AD, Bonjour S, Lysek DA, Fiorito F, Wüthrich K.(2005) Prion protein NMR structures of elk and of mouse/elk hybrids. Proc Natl Acad Sci USA 102:646–650.
  94. Christen B, Pérez DR, Hornemann S, Wüthrich K.(2008) NMR structure of the bank vole prion protein at 20 °C contains a structured loop of residues 165–171. J Mol Biol 383:306–312.
  95. Christen B, Hornemann S, Damberger FF, Wüthrich K.(2009) Prion protein NMR structure from tammar wallaby (Macropus eugenii) shows that the β2–α2 loop is modulated by long-range sequence effects. J Mol Biol 389:833–845.
  96. Pérez DR, Damberger FF, Wüthrich K (2010) Horse prion protein NMR structure and comparisons with related variants of the mouse prion protein. J Mol Biol 400:121–128.
  97. Wen Y, et al.(2010) Unique structural characteristics of the rabbit prion protein. J Biol Chem 285:31682–31693.
  98. m. Joaquín Castilla, Paula Saá & Claudio Soto. Detection of prions in blood. 2005.Nature Medicine volume 11, pages 982–985.
  99. True HL, Lindquist SL. A yeast prion provides a mechanism for genetic variation and phenotypic diversity, Nature, 2000, vol. 407 (pg. 477-83)
  100. Chiti F, Webster P, Taddei N, et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils, Proc Natl Acad Sci USA, 1999, vol. 96 (pg. 3590-4)
  101. Hope, L. J. Morton, C. F. Farquhar, G. Multhaup, K. Beyreuther, and R. H. Kimberlin, “The major polypeptide of scrapie-associated fibrils (SAF) has the same size, charge distribution and N-terminal protein sequence as predicted for the normal brain protein (PrP),” EMBO Journal, vol. 5, no. 10, pp. 2591–2597, 1986.
  102. R. Riek, S. Hornemann, G. Wider, M. Billeter, R. Glockshuber, and K. Wuthrich, “NMR structure of the mouse prion protein domain PrP(121-231),” Nature, vol. 382, no. 6587, pp. 180–182, 1996.
  103. Y. Bounhar, Y. Zhang, C. G. Goodyer, and A. LeBlanc, “Prion protein protects human neurons against Bax-mediated apoptosis,” Journal of Biological Chemistry, vol. 276, no. 42, pp. 39145–39149, 2001.
  104. M. Diarra-Mehrpour, S. Arrabal, A. Jalil et al., “Prion protein prevents human breast carcinoma cell line from tumor necrosis factor α-induced cell death,” Cancer Research, vol. 64, no. 2, pp. 719–727, 2004.
  105. Sattar, Hussain A. (2011). Fundamentals of Pathology. Chicago: Pathoma LLC. p. 187.
  106. Mead S, Rudge P (April 2017). "CJD mimics and chameleons". Practical Neurology. 17 (2): 113–121.
  107. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". Retrieved 2018-01-13.
  108. Satoh J, Kurohara K, Yukitake M, Kuroda Y (1999). "The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture". European Neurology. 41 (4): 216–25.
  109. Geschwind MD, Martindale J, Miller D, DeArmond SJ, Uyehara-Lock J, Gaskin D, Kramer JH, Barbaro NM, Miller BL (2003). "Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease". Archives of Neurology. 60 (6): 813–6.
  110. Chitravas N, Jung RS, Kofskey DM, Blevins JE, Gambetti P, Leigh RJ, Cohen ML (2011). "Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease". Annals of Neurology. 70 (3): 437–44.
  111. Sano K, Satoh K, Atarashi R, Takashima H, Iwasaki Y, Yoshida M, Sanjo N, Murai H, Mizusawa H, Schmitz M, Zerr I, Kim YS, Nishida N (2013-01-25). "Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay". PLOS ONE. 8 (1): e54915.
  112. Foutz A, Appleby BS, Hamlin C, Liu X, Yang S, Cohen Y, Chen W, Blevins J, Fausett C, Wang H, Gambetti P, Zhang S, Hughson A, Tatsuoka C, Schonberger LB, Cohen ML, Caughey B, Safar JG (2017). "Diagnostic and prognostic value of human prion detection in cerebrospinal fluid". Annals of Neurology. 81 (1): 79–92.
  113. Bongianni M, Orrù C, Groveman BR, Sacchetto L, Fiorini M, Tonoli G, Triva G, Capaldi S, Testi S, Ferrari S, Cagnin A, Ladogana A, Poleggi A, Colaizzo E, Tiple D, Vaianella L, Castriciano S, Marchioni D, Hughson AG, Imperiale D, Cattaruzza T, Fabrizi GM, Pocchiari M, Monaco S, Caughey B, Zanusso G (February 2017). "Diagnosis of Human Prion Disease Using Real-Time Quaking-Induced Conversion Testing of Olfactory Mucosa and Cerebrospinal Fluid Samples". JAMA Neurology. 74 (2): 155–162.
  114. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sáanchez-Valle R, Mitrováa E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Bodemer M, Slivarichová D, Saiz A, Calero M, Ingrosso L, Knight R, Janssens AC, van Duijn CM, Zerr I (August 2006). "CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease". Neurology. 67 (4): 637–43.
  115. Tattum MH, Jones S, Pal S, Khalili-Shirazi A, Collinge J, Jackson GS (December 2010). "A highly sensitive immunoassay for the detection of prion-infected material in whole human blood without the use of proteinase K" (PDF). Transfusion. 50(12): 2619–27.
  117. Soto, C. Diagnosing prion diseases: needs, challenges and hopes. Nat Rev Microbiol 2, 809–819 (2004).